Audrey Desgranges

CEO at McSAF Inside® Oncology

As an engineer specializing in organic chemistry and formulation, Audrey has evolved in a mixed environment combining R&D and the valorisation of patented technologies within academic teams and industry (Boehringer Ingelheim). In late 2017, Audrey joined McSAF and is in charge of operations.

In 2018, she initiates a collaboration between McSAF and academic teams of researchers and clinicians to evaluate the relevance of ADC strategy in Merkel Cell Carcinoma using McSAF bioconjugation tools via CD56 targeting. Then, she identified and planed project phases from discovery to clinical via identifying and interacting with external experts for ADCITMER® evaluation. She will convert her position as CEO to lead the development of ADCITMER® joining McSAF Inside Oncology the dedicated affiliate of McSAF.